Early payer scientific advice procedures – which one is most suited for pharmaceutical companies?
Pharmaceutical companies are increasingly seeking payer guidance to provide insights on how to build payer value into the clinical trial program. There are multiple ways to seek payer guidance throughout clinical development, either at an EU-wide or a country-specific level.
The objective of this research was to understand the processes and outputs from different European payer scientific advice procedures (PSAPs) to determine the most suitable approach for pharmaceutical companies.